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Abstract
Background: Carotid intima-media thickness (IMT) is an useful surrogate marker of cardiovascular disease.
Associations between uric acid (UA), metabolic syndrome (MetS) and carotid IMT have been reported, but findings
regarding the relationship have been inconsistent.
Methods: A total of 1,579 Japanese elderly subjects aged ≥65 years {663 men aged, 78 ± 8 (mean ± standard
deviation) years and 916 women aged 79 ± 8 years} were divided into 4 groups according to UA quartiles. We first
investigated the association between UA concentrations and confounding factors including MetS; then, we
assessed whether there is an independent association of UA with carotid IMT and atherosclerosis in participants
subdivided according to gender and MetS status.
Results: Carotid IMT was significantly increased according to the quartiles of UA in both genders without MetS
and women with MetS. Multivariate logistic regression analysis showed that odds ratio (OR) {95% confidence
interval (CI)} in men for carotid atherosclerosis was significantly increased in the third (OR, 1.75; 95% CI, 1.02-3.02),
and fourth quartiles (OR, 2.01; 95% CI, 1.12-3.60) of UA compared with that in the first quartile of UA, and the OR
in women was significantly increased in the fourth quartile (OR, 2.10; 95% CI, 1.30-3.39). Similarly, the ORs were
significantly associated with increasing quartiles of UA in both genders without MetS, but not necessarily increased
in those with MetS.
Conclusions: UA was found to be an independent risk factor for incidence of carotid atherosclerosis in both
genders without MetS.
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Introduction
Metabolic syndrome (MetS) is a cluster of metabolic
abnormalities defined as the clustering of several cardio-
vascular risk factors in an individual that include visceral
obesity, insulin resistance, raised blood pressure (BP),
hypertriglyceridemia, low high-density lipoprotein
(HDL) cholesterolemia, and impaired fasting plasma glu-
cose (FPG) [1,2], and that it is a predictor of cardiovas-
cular disease (CVD) [3-5]. Population-based studies have
shown that MetS is quite common, affecting 13.3~24.4%
of Japanese men ≥30 years of age [6], and its prevalence
is increasing with the continuous increase in obesity
prevalence in Japan.
Uric Acid (UA) is the metabolic end product of purine
metabolism in humans; excess accumulation can lead to
v a r i o u sd i s e a s e s[ 7 ] .M a n yp r e v i o u ss t u d i e sh a v es h o w n
that increased UA levels are also associated with compo-
nents of MetS and often accompanied by obesity, raised
BP [8], hyperlipidemia [9], glucose intolerance [10], and
CVD clustering [11], all of which play a causal role in
the pathogenesis of CVD. Thus, UA seems to be merely
an independent risk factor or marker for atherosclerosis
[12,13]. However, its importance as a risk factor is still
controversial. Sakata et al. showed that UA levels are
not related to increased risk of death from all causes,
including CVD and stroke in 8,172 Japanese participants
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more strongly associated with MetS in women than in
men, and associated with the prevalence of carotid
atherosclerosis {intima-media thickness (IMT) ≥1.0 mm}
only in men without MetS but not in men with MetS or
in women with or without MetS [15]. Associations
between UA, MetS and carotid IMT have been reported,
but few of the studies have been conducted in Japanese
subjects.
In the present study, we first investigated the associa-
tion between UA levels and confounding factors includ-
ing MetS; currently defined as at least 3 of the 5
following conditions: visceral obesity, raised BP, hyper-
triglyceridemia, low HDL cholesterolemia, and impaired
FPG. In addition, we also assessed whether there is an
independent association of UA with carotid athero-
sclerosis in individuals subdivided according to gender
and MetS status.
Materials and methods
Subjects
Subjects for this investigation were recruited from
among consecutive elderly patients aged ≥65 years vis-
ited the medical department of Seiyo Municipal Nomura
Hospital. Participants with severe cardio-renal or nutri-
tional disorders that would affect BP, lipid and glucose
metabolism were excluded. Thus, 1,579 patients were
enrolled in the study. All procedures were approved by
the Ethics Committee of Seiyo Municipal Nomura Hos-
pital, and written informed consent was obtained from
each subject.
Evaluation of Risk Factors
Information on demographic characteristics and risk
factors were collected using the clinical files in all cases.
Body mass index (BMI) was calculated by dividing
weight (in kilograms) by the square of the height (in
meters). We measured BP in the right upper arm of
patients in a sedentary posture using a standard sphyg-
momanometer or an automatic oscillometric BP recor-
der. Smoking status was defined as the number of
cigarette packs per day multiplied by the number of
years smoked (pack·year) irrespective of the differentia-
tion of current and past smoking status: never, light (<
20 pack·year), heavy (≥20 pack·year). Alcohol consump-
tion was classified into non-drinker and drinker (avail-
able data, n = 1,145). Histories of antihypertensive,
antilipidemic, and antidiabetic medication use were also
evaluated. Moreover, ischemic stroke and ischemic heart
disease were defined as CVD. Total cholesterol (T-C),
triglyceride (TG), HDL cholesterol (HDL-C), FPG, and
UA were measured under a fasting condition. Low-den-
sity lipoprotein cholesterol (LDL-C) level was calculated
by the Friedewald formula [16], and patients with TG
levels ≥400 mg/dl were excluded. The mean UA was
significantly lower in women [5.1 ± 2.0 {mean ± stan-
dard deviation (SD)} mg/dl] than in men (5.7 ± 2.0 mg/
dl; p < 0.001). Therefore, sex-specific quartiles of UA
were used. The mean (range) UA values of 3.5 (0.8 to
4.3), 5.0 (4.4 to 5.5), 6.1 (5.6 to 6.8), and 8.4 (6.9 to
16.1) mg/dl were used for men, and 3.1 (0.5 to 3.8), 4.3
(3.9 to 4.7), 5.3 (4.8 to 6.0), and 7.7 (6.1 to 15.4) were
used for women (Table 1).
Ultrasound image analysis
An ultrasonograph (Hitachi EUB-565, Aloka SSD-2000,
or Prosound-a6) equipped with a 7.5 MHz linear type
B-mode probe was used by a specialist in ultrasonogra-
phy to evaluate sclerotic lesions of the common carotid
arteries on a day close to the day of blood biochemistry
analysis (within 2 days). Patients were asked to assume a
supine position, and the bilateral carotid arteries were
observed obliquely from the anterior and posterior
directions. We measured the thickness of the intima-
media complex (IMT) on the far wall of the bilateral
common carotid artery about 10 mm proximal to the
bifurcation of the carotid artery (as the image at that
site is more clearly depicted than that at the near wall)
[17,18] as well as the wall thickness near the 10 mm
point on a B-mode monitor. We then used the mean
value for analysis. Carotid plaques were considered as
localized thickening and the echo luminance included
those equal to high echogenic structures encroaching
into the vessel lumen through common carotid artery to
carotid bifurcation [17]. Carotid atherosclerosis was
defined as IMT ≥1.0 mm or plaque lesion [17-19].
MetS
We applied condition-specific cutoff points for MetS
based on the modified criteria of the National Cholesterol
Education Program’s Adult Treatment Panel (NCEP-ATP)
III report [2]. MetS was defined as subjects with at least
three or more of the following five conditions: 1) obesity:
BMI ≥25.0 kg/m
2 according to the guidelines of the Japa-
nese Society for the Study of Obesity (waist circumference
was not available in this study) [20,21]; 2) raised BP with a
systolic BP (SBP) ≥130 mmHg and/or diastolic BP (DBP)
≥85 mmHg, and/or current treatment for hypertension; 3)
hypertriglyceridemia with a TG level ≥150 mg/dL; 4) low
HDL cholesterolemia with a HDL-C level < 40 mg/dL in
men and < 50 mg/dL in women and/or current treatment
for dyslipidemia; and 5) impaired fasting glucose with a
FPG level ≥100 mg/dL and/or current treatment for
diabetes.
Statistical analysis
All values are expressed as the mean ± standard devia-
tion (SD), unless otherwise specified, and in the cases of
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the data are shown as median (interquartile range)
values. In all analyses, parameters with non-normal dis-
tributions were used after log-transformation. Statistical
analysis was performed using PASW Statistics 17.0 (Sta-
tistical Package for Social Science Japan, Inc., Tokyo,
Japan). The differences of means and prevalence among
t h eg r o u p sw e r ea n a l y z e db yA N O V Aa n dc
2 test,
respectively, and A post hoc analysis was performed with
Dunnett’s test. A multivariate logistic regression analysis
was employed to evaluate the contribution of confound-
ing risk factors (e.g., age, BMI, smoking status, SBP,
DBP, antihypertensive medication, LDL-C, HDL-C, TG,
antilipidemic medication, FPG, antidiabetic medication,
and history of CVD) for carotid atherosclerosis. A value
of p < 0.05 was considered significant.
Results
Background of Subjects
Table 1 shows the clinical characteristics of the 663
male and 916 female subjects. Ages of the enrolled sub-
jects ranged with a mean of 79 ± 8 years (men, 78 ± 8
years; women, 79 ± 8 years; P < 0.001). In men, age,
prevalence of antihypertensive medication, and TG
showed a gradual increasing trend. In women, age, pre-
valence of antihypertensive medication, TG and
Table 1 Characteristics of subjects
Men Quartile of serum uric acid Women Quartile of serum
uric acid
Uric acid range (mg/
dL)
UA-1
0.8-4.3
N = 169
UA-2
4.4-5.5
N = 171
UA-3
5.6-6.8
N = 163
UA-4
6.9-16.1
N = 160
P for
trend*
UA-1
0.5-3.8
N = 247
UA-2
3.9-4.7
N = 213
UA-3
4.8-6.0
N = 235
UA-4
6.1-15.4
N = 221
P for
trend*
Age (years) 76 ± 8 78 ± 7 78 ± 8 79 ± 7 0.004 79 ± 8 78 ± 8 79 ± 8 82 ± 8 <
0.001
Body mass index†(kg/m
2) 21.3 ± 4.6 21.9 ± 3.2 21.9 ± 3.9 21.8 ± 4.0 0.372 21.2 ± 3.6 22.1 ± 3.4 22.8 ± 4.8 22.3 ± 4.8 <
0.001
Smoking status‡(never/
light/heavy, %)
26.0/20.7/
53.3
32.2/19.9/
48.0
36.2/17.8/
46.0
35.6/16.9/
47.5
0.517 99.2/0.4/
0.4
96.2/0.5/
3.3
65.7/1.3/
3.0
93.7/2.7/
3.6
0.043
Alcohol consumption¶, N
(%)
78 (67.8) 70 (60.9) 65 (59.1) 65 (66.3) 0.470 1 (0.6) 3 (1.8) 6 (3.3) 5 (2.8) 0.286
Systolic blood pressure
(mmHg)
132 ± 22 141 ± 22 139 ± 24 136 ± 25 0.003 138 ± 21 139 ± 20 138 ± 21 136 ± 28 0.552
Diastolic blood pressure
(mmHg)
76 ± 14 78 ± 13 77 ± 13 76 ± 14 0.672 76 ± 13 76 ± 11 76 ± 13 72 ± 16 0.001
Antihypertensive
medication, N (%)
65 (38.5) 75 (43.9) 88 (54.0) 82 (51.3) 0.019 116 (47.0) 105 (49.3) 140 (59.6) 146 (66.1) <
0.001
Total cholesterol (mg/dl) 167 ± 46 168 ± 42 164 ± 41 171 ± 45 0.505 190 ± 40 188 ± 42 193 ± 43 181 ± 44 0.025
LDL-cholesterol (mg/dl) 102 ± 38 104 ± 33 95 ± 35 105 ± 38 0.061 118 ± 33 114 ± 35 120 ± 37 110 ± 35 0.016
Triglyceride (mg/dl) 68 (52-93) 73 (56-98) 76 (57-112) 89 (69-127) <
0.001
69 (54-93) 80 (59-
109)
92 (69-
124)
94 (67-
120)
<
0.001
HDL-cholesterol (mg/dl) 49 ± 19 47 ± 15 51 ± 18 45 ± 15 0.024 57 ± 17 56 ± 18 53 ± 15 51 ± 17 <
0.001
Antilipidemic drug use, N
(%)
9 (5.3) 7 (4.1) 8 (4.9) 8 (5.0) 0.959 17 (6.9) 13 (6.1) 17 (7.2) 26 (11.8) 0.115
Fasting plasma glucose
(mg/dl)
119 (98-
152)
112 (95-
141)
113 (96-
150)
115 (96-
139)
0.404 112 (97-
146)
108 (94-
140)
109 (92-
130)
118 (97-
155)
0.061
Antidiabetic medication,
N (%)
50 (29.6) 35 (20.5) 29 (17.8) 37 (23.1) 0.063 47 (19.0) 48 (22.5) 43 (18.3) 59 (26.7) 0.112
Metabolic syndrome, N
(%)
32 (18.9) 50 (29.2) 44 (27.0) 54 (33.8) 0.022 62 (25.1) 71 (33.3) 87 (37.0) 97 (43.9) <
0.001
Cardiovascular disease, N
(%)
65 (38.5) 85 (49.7) 82 (50.3) 83 (51.9) 0.055 87 (35.2) 84 (39.4) 97 (41.3) 91 (41.2) 0.448
Ischemic stroke,
N (%)
59 (34.9) 74 (43.3) 73 (44.8) 75 (46.9) 0.131 77 (31.2) 73 (34.3) 78 (33.2) 69 (31.2) 0.869
Ischemic heart
disease,
N (%)
11 (6.5) 15 (8.8) 17 (10.4) 16 (10.0) 0.592 15 (6.1) 16 (7.5) 21(8.9) 30 (13.6) 0.031
LDL, low-density lipoprotein; HDL, high-density lipoprotein. Plus-minus values are means ± standard deviation. †Body mass index was calculated using weight in
kilograms divided by the square of the height in meters. ‡Smoking status: daily consumption (pack)×duration of smoking (year): never, light (< 20 pack year),
and heavy (≥20 pack·year). ¶Alcohol consumption was classified into non-drinker and drinker (available data, n = 1,145). Data for triglycerides and fasting plasma
glucose were skewed, and are presented as the median (interquartile range) and were log-transformed for analysis. *P-value: ANOVA or c
2-test.
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increasing trend and HDL-C showed a gradual decrease.
T h ep r e v a l e n c eo fM e t Sa l s os h o w e dag r a d u a li n c r e a s -
ing according to the UA quartiles in both genders.
There were no inter-group differences in prevalence of
alcohol consumption, FPG, prevalence of antidiabetic
and antilipidemic medication in both genders.
Carotid atherosclerosis of subjects according to quartile
of UA
As shown in Table 2, carotid IMT was significantly
increased according to the UA quartiles in both genders
without MetS and in women with MetS, but was not
necessarily increased in men with MetS. As shown in
Figure 1, the prevalence of carotid atherosclerosis was
significantly increased with increased UA quartile in
both genders without MetS.
Adjusted-odds ratio for carotid atherosclerosis according
to quartile of UA and MetS by gender
In Table 3, to examine possible associations between
quartiles of UA and the incidence of carotid athero-
sclerosis after subdivision of the subjects according to
MetS status, multivariate logistic regression analysis was
performed adjusted for age, gender, BMI, smoking sta-
tus, SBP, DBP, antihypertensive medication, LDL-C,
HDL-C, TG, antilipidemic medication, FPG, antidiabetic
medication, and history of CVD. In men, ORs (95% CI)
were significantly increased in the third {1.75 (1.02-
3.02)} and fourth quartiles {2.01 (1.12-3.60)} of UA com-
pared with that in the first quartile, and in women the
OR was significantly increased only in the fourth quar-
tile {2.10 (1.30-3.39)}. Similarly, the ORs were signifi-
cantly associated with increasing quartiles of UA in both
genders without MetS, but not necessarily increased in
those with MetS.
Adjusted-odds ratio of subgroups for carotid
atherosclerosis according to quartile of UA by gender
Next, to control potential confounding factors by age,
BMI, history of CVD, and medication, the data were
further stratified by their values (Table 4). In men, the
ORs for carotid atherosclerosis were significant in sub-
groups of age ≥75 years, BMI ≥ 25 kg/m
2,n oh i s t o r yo f
CVD, and absence of medication, and in women the
ORs were significant in subgroups of age < 75 years,
BMI ≥25 kg/m
2, regardless of history of CVD, presence
of medication.
Discussion
MetS, representing a cluster of visceral obesity, raised
BP, dyslipidemia and glucose intolerance induced by
insulin resistance, is a common basis for the develop-
ment of atherosclerosis, especially CVD [3-5]. In our
study, MetS as defined by the modified NCEP-ATP III
report criteria was present in 27.1% of men and 34.6%
of women. We found 2 results from this cross-sectional
data. First, sex-specific UA quartiles are associated with
various risk factors and the prevalence of MetS. Second,
UA levels might be associated with carotid atherosclero-
sis independently of other risk factors in both genders
without MetS.
Several previous studies have reported possible asso-
ciations between hyperuricemia and the prevalence of
MetS [22-24]. In a prospective study of 8,429 men and
1,260 women aged 20-82 years, 1,120 men and 44
women developed MetS during a mean follow-up of 5.7
years, and men with UA levels ≥6.5 mg/dL had a 1.60-
fold increase in risk of MetS (95% CI, 1.34-1.91) as com-
pared with those who had levels < 5.5 mg/dL (P for
trend < 0.001), and women with UA levels ≥4.6 mg/dL
had a 2.29-fold higher risk of MetS (P for trend = 0.02)
[22]. These findings suggest that hyperuricemia may be
Table 2 Carotid intima-media thickness of subjects according to quartile of uric acid and metabolic syndrome by
gender
Quartile of serum uric acid
Uric acid range
Men (mg/dL)
Women(mg/dL)
UA-1
0.8-4.3
0.5-3.8
UA-2
4.4-5.5
3.9-4.7
UA-3
5.6-6.8
4.8-6.0
UA-4
6.9-16.1
6.1-15.4
All subjects
Men, N = 663 1.02 ± 0.20 # 1.06 ± 0.26 1.03 ± 0.20 § 1.13 ± 0.27 < 0.001
Women, N = 916 0.97 ± 0.18 # 0.98 ± 0.20 # 0.99 ± 0.19 § 1.06 ± 0.25 < 0.001
Subjects without metabolic syndrome (< 3 components of metabolic syndrome)
Men, N = 483 1.01 ± 0.20 # 1.07 ± 0.29 1.03 ± 0.20 § 1.15 ± 0.28 < 0.001
Women, N = 599 0.95 ± 0.18 § 0.97 ± 0.19 † 0.99 ± 0.20 1.04 ± 0.21 0.002
Subjects with metabolic syndrome (≥3 components of metabolic syndrome)
Men, N = 180 1.07 ± 0.23 1.04 ± 0.14 1.05 ± 0.19 1.10 ± 0.24 0.487
Women, N = 317 1.01 ± 0.18 0.99 ± 0.22 † 1.00 ± 0.19 † 1.10 ± 0.23 0.004
† P < 0.05; § P < 0.005; # P < 0.001 vs. the fourth quartile (UA-4). *P-value: ANOVA and Dunnett’s test was used for the pos hoc analysis.
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Figure 1 Prevalence of carotid atherosclerosis according to quartile of uric acid (UA) and metabolic syndrome by gender.T h e
prevalence of carotid atherosclerosis was also significantly increased with increased UA quartile only in both genders without metabolic
syndrome.
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specific analyses were also required because at all ages,
t h eU Al e v e li sh i g h e ri nm e nt h a ni nw o m e n[ 2 2 , 2 3 ] .
We cannot explain the underlying mechanism that
accounts for the gender difference from this study. A
partial explanation for this result could be alcohol con-
sumption, which is more likely to be higher in men, the
use of antihypertensive medications such as diuretics,
which are known to increase UA levels [25], and the
influence of sex hormones [26]. Furthermore, UA tends
to positively associate with FPG in subjects without dia-
betes and negatively associate with FPG in subjects with
diabetes [27]. In our study, the analysis was performed
after adjusting for FPG, medication, and alcohol
Table 3 Adjusted-odds ratio (95% CI) for carotid atherosclerosis according to quartile of uric acid and metabolic
syndrome by gender
Quartile of serum uric acid
Uric acid range
Men (mg/dL)
Women (mg/dL)
UA-1
0.8-4.3
0.5-3.8
UA-2
4.4-5.5
3.9-4.7
UA-3
5.6-6.8
4.8-6.0
UA-4
6.9-16.1
6.1-15.4
All subjects
Men, N = 663 1 (reference) 1.06 (0.63-1.76) 1.75 (1.02-3.02) † 2.01 (1.12-3.60) †
Women, N = 916 1 (reference) 1.44 (0.94-2.21) 1.29 (0.84-1.98) 2.10 (1.30-3.39)§
Subjects without metabolic syndrome (< 3 components of metabolic syndrome)
Men, N = 483 1 (reference) 0.92 (0.51-1.67) 2.00 (1.03-3.87) † 2.54 (1.21-5.34) ‡
Women, N = 599 1 (reference) 1.78 (1.06-3.00)† 1.41 (0.83-2.40) 2.54 (1.35-4.78)§
Subjects with metabolic syndrome (≥3 components of metabolic syndrome)
Men, N = 180 1 (reference) 2.14 (0.67-6.81) 1.55 (0.50-4.83) 2.26 (0.72-7.10)
Women, N = 317 1 (reference) 0.81 (0.36-1.79) 1.12 (0.51-2.49) 1.43 (0.62-3.27)
CI, confidential interval. Adjusted for age, body mass index, smoking status, systolic blood pressure, diastolic blood pressure, antihypertensive medication, LDL-
cholesterol, HDL-cholesterol, triglycerides, antilipidemic medication, fasting plasma glucose, antidiabetic medication, and history of cardiovascular disease. † P <
0.05; ‡ P < 0.01; § P < 0.005 vs. the first quartile (UA-1).
Table 4 Adjusted-odds ratio (95% CI) of subgroups for carotid atherosclerosis according to quartile of uric acid by
gender
Men Women
Uric acid range
(mg/dl)
Characteristics
N UA-1
0.8-4.3
UA-2
4.4-5.5
UA-3
5.6-6.8
UA-4
6.9-16.1
P for
trend*
N UA-1
0.5-3.8
UA-2
3.9-4.7
UA-3
4.8-6.0
UA-4
6.1-15.4
P for
trend*
Age
< 75 years 241 1
(reference)
0.72 (0.33-
1.60)
0.99 (0.46-
2.14)
1.08 (0.44-
2.64)
0.802 293 1
(reference)
1.63 (0.80-
3.34)
1.35
(0.65-2.79)
4.11 (1.61-
10.5) §
0.020
≥75 years 422 1
(reference)
1.33 (0.66-
2.67)
2.76 (1.21-
6.29) †
3.00 (1.34-
6.70) ‡
0.015 623 1
(reference)
1.49 (0.85-
2.63)
1.24
(0.71-2.17)
1.57 (0.87-
2.83)
0.400
Body mass index
<25 kg/m
2 557 1
(reference)
1.08 (0.62-
1.88)
1.79 (0.98-
3.26)
1.61 (0.86-
2.99)
0.162 729 1
(reference)
1.46 (0.90-
2.35)
1.38
(0.85-2.26)
1.51 (0.88-
2.59)
0.314
≥25 kg/m
2 106 1
(reference)
1.54 (0.23-
10.3)
3.17 (0.49-
20.4)
15.1 (1.60-
143) †
0.030 187 1
(reference)
1.92 (0.64-
5.78)
1.77
(0.63-4.99)
8.66 (2.44-
30.8) #
0.001
History of CVD
No 348 1
(reference)
1.34 (0.72-
2.50)
2.47 (1.26-
4.86) ‡
2.02 (1.01-
4.06) †
0.037 557 1
(reference)
2.00 (1.18-
3.37) †
1.13
(0.68-1.90)
1.95 (1.10-
3.45) †
0.016
Yes 315 1
(reference)
0.66 (0.25-
1.75)
0.93 (0.33-
2.62)
1.98 (0.63-
6.28)
0.185 359 1
(reference)
0.87 (0.40-
1.85)
1.79
(0.77-4.15)
2.93 (1.08-
7.92) †
0.037
Medication
No 279 1
(reference)
1.23 (0.59-
2.54)
2.52 (1.09-
5.82) †
3.71 (1.47-
9.35) ‡
0.011 333 1
(reference)
1.69 (0.84-
3.41)
1.97
(0.93-4.15)
0.95 (0.41-
2.18)
0.178
Yes 384 1
(reference)
0.89 (0.41-
1.90
1.27 (0.60-
2.70)
1.19 (0.54-
2.64)
0.786 583 1
(reference)
1.36 (0.77-
2.40)
1.15
(0.66-1.99)
2.84 (1.52-
5.33)§
0.004
CVD, cardiovascular disease. Medications include antihypertensive, antilipidemic, and antidiabetic medications. Adjusted for age, body mass index, smoking
status, systolic blood pressure, diastolic blood pressure, antihypertensive medication, LDL-cholesterol, HDL-cholesterol, triglycerides, antilipidemic medication,
fasting plasma glucose, antidiabetic medication, and history of cardiovascular disease. † P < 0.05; ‡ P < 0.01; § P < 0.005; # P < 0.001 vs. the first quartile (UA-1).
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Page 6 of 9consumption (data not shown), but the results were
similar. Effects of alcohol consumption or sex hormone
require further investigation in the future.
Hyperuricemia is well recognized as a risk factor for
atherosclerotic diseases such as CVD [12,13] and carotid
atherosclerosis [28-34]. However, whether UA is an
independent risk factor for cardiovascular mortality is
still a controversy, as previous studies suggest that UA
is associated with other cardiovascular risk factors
[8-11] despite the strengths of the associations. In cross-
sectional screening data from 8,144 individuals, the pre-
valence of carotid plaque was significantly higher with
increasing quartiles of UA level, in men without MetS
but not in men with MetS or in women with or without
MetS [32]. On the other hand, in a prospective study of
4,966 men (79% white) and 6,522 women (74% white)
who were aged 45 to 64 years at baseline, after adjust-
ment for known risk factors that correlate with UA, the
association of UA with B-mode ultrasound carotid IMT
became non significant in white women and much
weaker and not statistically significant in black women
and white men [33]. These conflicting findings are partly
related to methodological differences and to participant
characteristics. In addition, as UA revels relate with
increasing numbers of or special metabolic risk factors,
the effect of UA on carotid atherosclerosis might
become negligible.
The mechanisms by which UA reflects the risk for
carotid atherosclerosis are not completely understood
even though previous studies have been done in this
area, and it is unclear whether high UA levels promote
or protect against the development of CVD, or simply
act as a passive marker of increased risk. UA regulates
critical proinflammatory pathways in vascular smooth
muscle cells. Hyperuricemia might be partially responsi-
ble for the proinflammatory endocrine imbalance in the
adipose tissue and vascular smooth muscle cells [35,36]
which is an underlying mechanism of the low-grade
inflammation and insulin resistance in subjects with the
MetS, and causes dysfunction of endothelial cells. In
addition, experimental evidence suggests that adverse
effects of UA on the vasculature have been linked to
increased chemokine and cytokine expressions, induc-
tion of the renin-angiotensin system, and to increased
vascular C-reactive protein (CRP) expression [37]. UA
also promotes endothelial dysfunction through inactiva-
tion of NO and suppression of the proliferation of
endothelial cells [38]. Thus, arteriosclerosis induced by
hyperuricemia may be a novel mechanism for the devel-
opment of MetS and carotid atherosclerosis. However,
Nieto et al. demonstrated that the higher UA levels
seemed associated with elevated total serum antioxidant
capacity among individuals with carotid atherosclerosis
and be a powerful free radical scavenger in humans
[39]. These antioxidant properties of UA could be
expected to offer a number of benefits within the cardi-
ovascular system.
We need to be aware of the limitations in interpreting
the present results. First, based on its cross-sectional
study design, the present result is inherently limited in
its ability to elucidate causal relationships between risk
factors and carotid atherosclerosis. Second, since all par-
ticipants were patients, we could not eliminate the pos-
sible effects of underlying diseases (e.g., hypertension
and diabetes), alcohol consumption, medication (e.g.,
diuretics, antihyperuricemic and antilipidemic medica-
tions) and FPG on the result s .T h u s ,t h ea n a l y s i sw a s
performed after adjusting for confounding factors
including FPG and medication (e.g., antihypertensive,
antilipidemic, and antidiabetic medication). Third, we
used BMI ≥25 kg/m
2 to classify individuals with visceral
obesity because waist circumference measurements were
not available, which might have caused an under or over
estimation of the effect of visceral obesity on MetS. In
fact, the prevalence of MetS in women was higher than
those in men and general reports on Japanese [40].
Moreover, secondary prevention interventions after obe-
sity, raised BP, dyslipidemia and diabetes may be suc-
cessful in reducing risk factors, thus attenuating the
observed association of risk factors with diseases. These
points need to be addressed again in prospective popu-
lation-based studies.
In sum, we reported a significant association between
the clustering of cardiovascular risk factors known as
MetS and UA, and carotid IMT in subjects with risk
factors for atherosclerosis. In both genders that did not
h a v eM e t S ,U Aw a sf o u n dt ob ea ni n d e p e n d e n tr i s k
factor for the incidence of carotid atherosclerosis.
Serum UA confers an increased risk of cardiovascular
morbidity, and its identification may thus be important
for risk assessment and treatment of patients.
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